ATLANTA, March 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), http://www.geovax.com, an Atlanta based AIDS vaccine development company, is very pleased to announce the addition of Dr. Robert McNally as President and CEO effective 01 April 2008. Current President/CEO and company co-founder Don Hildebrand remains as Chairman of the GeoVax Board of Directors and will continue to be heavily involved in company development, growth and expansion plans in the AIDS vaccine arena.
"Dr. McNally is joining our team to provide additional expertise to guide our AIDS vaccine development into advanced Phase 2a human clinical trials which are being planned for mid 2008. His strong bio-technical, research and managerial experience at all corporate levels provides GeoVax with the depth of expertise required to move efficiently forward at an accelerated pace," stated Don Hildebrand, GeoVax Chairman/President/CEO.
Dr. Harriet Robinson, GeoVax co-founder and Senior Vice President of Research & Development stated, "It will be great having Dr. McNally on the team. He knows our company well, having served on our Board, and his technical and business expertise will be a very valuable asset moving forward."
Dr. McNally has been a member of the GeoVax Board of Directors since
2006 and was previously a co-founder and CEO of Cell Dynamics LLC and Cell
Design LLC companies specializing in GMP processing of human cells for
pharmaceutical and therapeutic applications. Dr. McNally was also
co-founder and Sr. Vice President of Clinical Research for CryoLife, Inc. a
pioneering company in transplantable human tissues. He has had previous
experience as European Regional Manager for Intermedics International, Inc.
and European Marketing Manager for Pacesetter Systems-Europe, Ltd. in the
UK. Dr. McNally serves as a member of the advisory boards of the Petit
Institute for Bioengineering and Dupree Col
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved